IQVIA Holdings Inc. $IQV Shares Sold by Terra Alpha Investments LLC

Terra Alpha Investments LLC lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 26.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 8,791 shares of the medical research company’s stock after selling 3,102 shares during the quarter. IQVIA makes up 2.0% of Terra Alpha Investments LLC’s investment portfolio, making the stock its 19th largest position. Terra Alpha Investments LLC’s holdings in IQVIA were worth $1,982,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Ameliora Wealth Management Ltd. acquired a new stake in IQVIA in the fourth quarter valued at $25,000. Physician Wealth Advisors Inc. lifted its holdings in IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 134 shares during the period. International Assets Investment Management LLC acquired a new stake in IQVIA in the fourth quarter valued at $27,000. Westside Investment Management Inc. lifted its holdings in IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 101 shares during the period. Finally, Measured Wealth Private Client Group LLC acquired a new stake in IQVIA in the third quarter valued at $30,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on IQV. JPMorgan Chase & Co. reduced their target price on IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a report on Friday, February 6th. UBS Group cut their price target on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Morgan Stanley set a $225.00 price target on IQVIA in a research note on Thursday, May 7th. Mizuho set a $215.00 price target on IQVIA in a research note on Monday, February 23rd. Finally, Weiss Ratings downgraded IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Buy” and an average price target of $225.69.

IQVIA Trading Down 0.7%

NYSE:IQV opened at $169.56 on Friday. The company has a market capitalization of $28.30 billion, a PE ratio of 21.01, a price-to-earnings-growth ratio of 1.63 and a beta of 1.18. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04. The stock has a fifty day simple moving average of $170.14 and a 200-day simple moving average of $199.19.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has authorized a stock repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.